David G Huntsman

List of Publications by Year in Descending Order

251 papers	23,393 citations	80 h-index	149 g-index
266 ext. papers	27,757 ext. citations	10 avg, IF	6.1 L-index

#	Paper	IF	Citations
251	Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention.. *JAMA Network Open*, **2022**, 5, e2147343	10.4	1
250	Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases.. *Gynecologic Oncology*, **2022**, 165, 376-384	4.9	2
249	Solving the genetic aetiology of hereditary gastrointestinal tumour syndromes- a collaborative multicentre endeavour within the project Solve-RD.. *European Journal of Medical Genetics*, **2022**, 104475	2.6	0
248	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 217-228	4	7
247	Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.. *Journal of Pathology*, **2021**,	9.4	3
246	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. *Cancer Epidemiology Biomarkers and Prevention*, **2021**,	4	2
245	ARID1A regulates R-loop associated DNA replication stress. *PLoS Genetics*, **2021**, 17, e1009238	6	13
244	Modelling hereditary diffuse gastric cancer initiation using transgenic mouse-derived gastric organoids and single-cell sequencing. *Journal of Pathology*, **2021**, 254, 254-264	9.4	2
243	Identification of a Locus Near Associated With Progression-Free Survival in Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 1669-1680	4	2
242	STING pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?. *Journal of Pathology: Clinical Research*, **2021**, 7, 548-555	5.3	2
241	Modeling High-Grade Serous Ovarian Carcinoma Using a Combination of Fallopian Tube Electroporation and CRISPR-Cas9-Mediated Genome Editing. *Cancer Research*, **2021**, 81, 5147-5160	10.1	3
240	Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome. *Modern Pathology*, **2021**, 34, 508-518	9.8	19
239	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. *Modern Pathology*, **2021**, 34, 194-206	9.8	6
238	Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. *Gynecologic Oncology*, **2021**, 160, 568-578	4.9	7
237	Whole-proteome analysis of mesonephric-derived cancers describes new potential biomarkers. *Human Pathology*, **2021**, 108, 1-11	3.7	3
236	Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. *Journal of Pathology*, **2021**, 253, 41-54	9.4	15
235	Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. *Nature Cancer*, **2021**, 2, 189-200	15.4	6

234	Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease. *Journal of Pathology: Clinical Research*, **2021**, 7, 243-252	5.3	7
233	Reply to "An alternative miRISC targets a cancer-associated coding sequence mutation in FOXL2". *EMBO Journal*, **2021**, 40, e107517	13	2
232	Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status. *Modern Pathology*, **2021**,	9.8	4
231	FOXL2 in adult-type granulosa cell tumour of the ovary: oncogene or tumour suppressor gene?. *Journal of Pathology*, **2021**, 255, 225-231	9.4	1
230	From biobank and data silos into a data commons: convergence to support translational medicine. *Journal of Translational Medicine*, **2021**, 19, 493	8.5	1
229	Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma. *Human Pathology*, **2020**, 101, 40-52	3.7	2
228	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. *Clinical Cancer Research*, **2020**, 26, 4402-4413	12.9	8
227	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). *Clinical Cancer Research*, **2020**, 26, 5411-5423	12.9	21
226	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. *British Journal of Cancer*, **2020**, 123, 793-802	8.7	16
225	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. *Gynecologic Oncology*, **2020**, 158, 702-709	4.9	5
224	The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity. *Cancer Research*, **2020**, 80, 3480-3491	10.1	10
223	Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada. *American Journal of Obstetrics and Gynecology*, **2020**, 223, 221.e1-221.e11	6.4	13
222	SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models. *Annual Review of Pathology: Mechanisms of Disease*, **2020**, 15, 467-492	34	23
221	Low-grade serous ovarian cancer: State of the science. *Gynecologic Oncology*, **2020**, 156, 715-725	4.9	28
220	Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. *Modern Pathology*, **2020**, 33, 1595-1605	9.8	40
219	p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns. *Modern Pathology*, **2020**, 33, 1649-1659	9.8	10
218	Non-coding somatic mutations converge on the PAX8 pathway in ovarian cancer. *Nature Communications*, **2020**, 11, 2020	17.4	17
217	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. *Journal of Clinical Investigation*, **2020**, 130, 2712-2726	15.9	45

216	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line. *PLoS ONE*, **2020**, 15, e0240412	3.7	1
215	Evaluation of human papillomavirus (HPV) prediction using the International Endocervical Adenocarcinoma Criteria and Classification system, compared to p16 immunohistochemistry and HPV RNA in-situ hybridization. *Journal of Pathology and Translational Medicine*, **2020**, 54, 480-488	2.9	2
214	Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism. *ELife*, **2020**, 9,	8.9	7
213	Use of Immunohistochemical Markers (HNF-1β, Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction. *International Journal of Gynecological Pathology*, **2020**, 39, 344-353	3.2	5
212	The coming 15 years in gynaecological pathology: digitisation, artificial intelligence, and new technologies. *Histopathology*, **2020**, 76, 171-177	7.3	3
211	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 97-104	4.9	19
210	Histotype-specific analysis of acid ceramidase expression in ovarian cancer. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2020**, 476, 855-862	5.1	2
209	Synthesis of diagnostic quality cancer pathology images by generative adversarial networks. *Journal of Pathology*, **2020**, 252, 178-188	9.4	15
208	Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours. *Journal of Pathology*, **2020**, 252, 201-214	9.4	13
207	Hereditary diffuse gastric cancer: updated clinical practice guidelines. *Lancet Oncology, The*, **2020**, 21, e386-e397	21.7	95
206	Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored. *Epidemiology*, **2020**, 31, 402-408	3.1	3
205	Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines. *Clinical Cancer Research*, **2020**, 26, 3908-3917	12.9	28
204	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line **2020**, 15, e0240412		
203	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line **2020**, 15, e0240412		
202	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line **2020**, 15, e0240412		
201	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line **2020**, 15, e0240412		
200	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019** , 10, 431	17.4	45
199	Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers. *Human Pathology*, **2019**, 92, 39-47	3.7	2

198	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. *Modern Pathology*, **2019**, 32, 1834-1846	9.8	21
197	Oncogenic mutations in histologically normal endometrium: the new normal?. *Journal of Pathology*, **2019**, 249, 173-181	9.4	60
196	Base excision repair deficiency signatures implicate germline and somatic aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. *Journal of Physical Education and Sports Management*, **2019**, 5,	2.8	17
195	Molecular profiling and molecular classification of endometrioid ovarian carcinomas. *Gynecologic Oncology*, **2019**, 154, 516-523	4.9	39
194	Germline deletion of in familial acute lymphoblastic leukemia. *Blood Advances*, **2019**, 3, 1039-1046	7.8	13
193	Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis. *EMBO Reports*, **2019**, 20, e48375	6.5	44
192	Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target. *Cancer Cell International*, **2019**, 19, 10	6.4	20
191	A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants. *International Journal of Cancer*, **2019**, 144, 2192-2205	7.5	11
190	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. *Journal of Clinical Investigation*, **2019**, 129, 223-229	15.9	62
189	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. *Cancer Research*, **2019**, 79, 505-517	10.1	28
188	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. *Mayo Clinic Proceedings*, **2018**, 93, 307-320	6.4	14
187	The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. *Clinical Cancer Research*, **2018**, 24, 2328-2341	12.9	32
186	DICER1 hot-spot mutations in ovarian gynandroblastoma. *Histopathology*, **2018**, 73, 306-313	7.3	9
185	TERT promoter mutation in adult granulosa cell tumor of the ovary. *Modern Pathology*, **2018**, 31, 1107-1115	9.8	27
184	Clear cell carcinomas of the ovary and kidney: clarity through genomics. *Journal of Pathology*, **2018**, 244, 550-564	9.4	27
183	Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. *Clinical Cancer Research*, **2018**, 24, 1932-1943	12.9	39
182	The molecular pathology of cancer: from pan-genomics to post-genomics. *Journal of Pathology*, **2018**, 244, 509-511	9.4	15
181	A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. *BMC Cancer*, **2018**, 18, 254	4.8	12

180	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. *BMC Cancer*, **2018**, 18, 347	4.8	42
179	High Frequency of Ovarian Cyst Development in Vhl;Snf5 Mice. *American Journal of Pathology*, **2018**, 188, 1510-1516	5.8	
178	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. *Journal of Pathology: Clinical Research*, **2018**, 4, 250-261	5.3	38
177	L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. *British Journal of Cancer*, **2018**, 119, 480-486	8.7	38
176	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
175	Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada. *American Journal of Obstetrics and Gynecology*, **2018**, 219, 172.e1-172.e8	6.4	15
174	Distinct developmental trajectories of endometriotic epithelium and stroma: implications for the origins of endometriosis. *Journal of Pathology*, **2018**, 246, 257-260	9.4	10
173	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. *Cell*, **2018**, 173, 1755-1769.e22	36.2	159
172	Histotype classification of ovarian carcinoma: A comparison of approaches. *Gynecologic Oncology*, **2018**, 151, 53-60	4.9	30
171	Changing Clinical Practice: Evaluation of Implementing Recommendations for Opportunistic Salpingectomy in British Columbia and Ontario. *International Journal of Gynecological Cancer*, **2018**, 28, 1101-1107	3.5	5
170	Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type. *Molecular Cancer Therapeutics*, **2018**, 17, 2767-2779	6.1	30
169	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. *British Journal of Cancer*, **2017**, 116, 524-535	8.7	18
168	Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. *Cancer*, **2017**, 123, 802-813	6.4	267
167	Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. *Annals of Medicine*, **2017**, 49, 435-447	1.5	36
166	Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma. *Molecular Cancer Research*, **2017**, 15, 250-258	6.6	39
165	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. *Nature Genetics*, **2017**, 49, 856-865	36.3	141
164	Cancer-Associated Mutations in Endometriosis without Cancer. *New England Journal of Medicine*, **2017**, 376, 1835-1848	59.2	310
163	The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. *Journal of Pathology*, **2017**, 242, 371-383	9.4	56

162	A structured latent model for ovarian carcinoma subtyping from histopathology slides. *Medical Image Analysis*, **2017**, 39, 194-205	15.4	16
161	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
160	APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. *Gynecologic Oncology*, **2017**, 147, 663-671	4.9	20
159	Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. *Journal of Pathology: Clinical Research*, **2017**, 3, 279-293	5.3	44
158	Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. *Science Signaling*, **2017**, 10,	8.8	37
157	LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers. *Gynecologic Oncology*, **2017**, 147, 642-647	4.9	7
156	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. *JAMA Oncology*, **2017**, 3, e173290	13.4	152
155	Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. *Scientific Reports*, **2017**, 7, 10574	4.9	18
154	ARID1A-mutated ovarian cancers depend on HDAC6 activity. *Nature Cell Biology*, **2017**, 19, 962-973	23.4	124
153	Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?. *Journal of Pathology*, **2017**, 243, 26-36	9.4	50
152	FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor. *Journal of Molecular Diagnostics*, **2017**, 19, 126-136	5.1	19
151	The disparate origins of ovarian cancers: pathogenesis and prevention strategies. *Nature Reviews Cancer*, **2017**, 17, 65-74	31.3	168
150	Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation. *PLoS ONE*, **2017**, 12, e0178989	3.7	9
149	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. *Oncotarget*, **2017**, 8, 64670-64684	3.3	5
148	Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. *Modern Pathology*, **2016**, 29, 1586-1593	9.8	59
147	Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. *Gynecologic Oncology*, **2016**, 143, 46-53	4.9	94
146	Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis. *Clinical Cancer Research*, **2016**, 22, 2865-73	12.9	93
145	An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. *International Journal of Gynecological Pathology*, **2016**, 35, 430-41	3.2	121

144	Rare cancers: a sea of opportunity. *Lancet Oncology, The*, **2016**, 17, e52-e61	21.7	60
143	Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. *Modern Pathology*, **2016**, 29, 302-14	9.8	85
142	Evidence of a genetic link between endometriosis and ovarian cancer. *Fertility and Sterility*, **2016**, 105, 35-43.e1-10	4.8	26
141	Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. *Journal of the National Cancer Institute*, **2016**, 108, djv428	9.7	81
140	Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction. *PLoS ONE*, **2016**, 11, e0153844	3.7	12
139	Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines. *American Journal of Cancer Research*, **2016**, 6, 2235-2251	4.4	12
138	Clinically-inspired automatic classification of ovarian carcinoma subtypes. *Journal of Pathology Informatics*, **2016**, 7, 28	4.4	3
137	Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. *Histopathology*, **2016**, 69, 727-738	7.3	40
136	BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer. *International Journal of Gynecological Cancer*, **2016**, 26, 825-32	3.5	32
135	Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience. *International Journal of Gynecological Pathology*, **2016**, 35, 209-21	3.2	24
134	Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research. *Scientific Reports*, **2016**, 6, 34949	4.9	72
133	The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. *Gynecologic Oncology*, **2016**, 141, 454-460	4.9	61
132	Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. *Nature Genetics*, **2016**, 48, 758-67	36.3	209
131	Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. *American Journal of Human Genetics*, **2016**, 98, 830-842	11	153
130	Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	37
129	Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. *Journal of Pathology*, **2016**, 238, 389-400	9.4	122
128	The genomic landscape of epithelioid sarcoma cell lines and tumours. *Journal of Pathology*, **2016**, 238, 63-73	9.4	27
127	Targeted mutation analysis of endometrial clear cell carcinoma. *Histopathology*, **2015**, 66, 664-74	7.3	63

126	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. *Journal of Medical Genetics*, **2015**, 52, 361-74	5.8	385
125	Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. *JAMA Oncology*, **2015**, 1, 23-32	13.4	401
124	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. *Molecular Cancer Therapeutics*, **2015**, 14, 1495-503	6.1	13
123	Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. *BMC Cancer*, **2015**, 15, 32	4.8	28
122	Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. *BMC Cancer*, **2015**, 15, 415	4.8	87
121	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. *Nature Reviews Cancer*, **2015**, 15, 668-79	31.3	581
120	Systematic analysis of somatic mutations impacting gene expression in 12 tumour types. *Nature Communications*, **2015**, 6, 8554	17.4	71
119	The oncogenic roles of DICER1 RNase IIIb domain mutations in ovarian Sertoli-Leydig cell tumors. *Neoplasia*, **2015**, 17, 650-60	6.4	43
118	Population distribution of lifetime risk of ovarian cancer in the United States. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 671-676	4	67
117	Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. *Nature*, **2015**, 518, 422-6	50.4	451
116	Categorization of cancer through genomic complexity could guide research and management strategies. *Journal of Pathology*, **2015**, 236, 397-402	9.4	4
115	Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. *American Journal of Surgical Pathology*, **2015**, 39, 1548-57	6.7	50
114	Recurrent DICER1 hotspot mutations in endometrial tumours and their impact on microRNA biogenesis. *Journal of Pathology*, **2015**, 237, 215-25	9.4	28
113	Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. *Oncotarget*, **2015**, 6, 37663-77	3.3	98
112	Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. *International Journal of Gynecological Cancer*, **2015**, 25, 1187-93	3.5	26
111	In-depth molecular profiling of the biphasic components of uterine carcinosarcomas. *Journal of Pathology: Clinical Research*, **2015**, 1, 173-85	5.3	51
110	Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. *Journal of Pathology*, **2015**, 236, 201-9	9.4	92
109	Using Somatic Mutations to Guide Treatment Decisions: Context Matters. *JAMA Oncology*, **2015**, 1, 275-6	13.4	13

108	Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. *Journal of Physical Education and Sports Management*, **2015**, 1, a000570	2.8	75
107	Cancer genomics: why rare is valuable. *Journal of Molecular Medicine*, **2015**, 93, 369-81	5.5	7
106	Loss of Sprouty2 in human high-grade serous ovarian carcinomas promotes EGF-induced E-cadherin down-regulation and cell invasion. *FEBS Letters*, **2015**, 589, 302-9	3.8	8
105	Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing. *PLoS ONE*, **2015**, 10, e0119689	3.7	32
104	Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. *American Journal of Obstetrics and Gynecology*, **2014**, 210, 471.e1-11	6.4	178
103	Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. *Nature Genetics*, **2014**, 46, 427-9	36.3	224
102	A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. *BMC Cancer*, **2014**, 14, 120	4.8	61
101	Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). *Rare Diseases (Austin, Tex)*, **2014**, 2, e967148		31
100	Germline mutations in MAP3K6 are associated with familial gastric cancer. *PLoS Genetics*, **2014**, 10, e1004669		46
99	TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. *Genome Research*, **2014**, 24, 1881-93	9.7	218
98	Boveri at 100: Theodor Boveri and genetic predisposition to cancer. *Journal of Pathology*, **2014**, 234, 142-5	9.4	8
97	A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. *Histopathology*, **2014**, 64, 380-8	7.3	29
96	Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1 and oestrogen receptor. *Histopathology*, **2014**, 64, 585-96	7.3	59
95	Diagnostic value of next-generation sequencing in an unusual sphenoid tumor. *Oncologist*, **2014**, 19, 623-30	5.7	17
94	Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. *BMC Cancer*, **2014**, 14, 982	4.8	21
93	ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. *Human Pathology*, **2014**, 45, 1258-68	3.7	28
92	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. *Modern Pathology*, **2014**, 27, 128-34	9.8	168
91	Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. *Orphanet Journal of Rare Diseases*, **2013**, 8, 33	4.2	33

90	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. *Lancet Oncology, The*, **2013**, 14, 853-62	21.7	248
89	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. *Nature Genetics*, **2013**, 45, 1226-1231	36.3	205
88	The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. *American Journal of Pathology*, **2013**, 182, 1163-70	5.8	55
87	Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. *Journal of Pathology*, **2013**, 229, 111-20	9.4	139
86	Familial rhabdoid tumour N'avant la lettreN from pathology review to exome sequencing and back again. *Journal of Pathology*, **2013**, 231, 35-43	9.4	49
85	An E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. *Journal of Pathology*, **2013**, 229, 621-9	9.4	138
84	FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. *Modern Pathology*, **2013**, 26, 860-7	9.8	58
83	Histotype-genotype correlation in 36 high-grade endometrial carcinomas. *American Journal of Surgical Pathology*, **2013**, 37, 1421-32	6.7	92
82	Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 1677-86	4	53
81	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nature Communications*, **2013**, 4, 1628	17.4	124
80	Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. *Journal of Pathology*, **2013**, 231, 21-34	9.4	292
79	Type-specific cell line models for type-specific ovarian cancer research. *PLoS ONE*, **2013**, 8, e72162	3.7	161
78	Beyond CDH1 Mutations: Causes of Hereditary Diffuse Gastric Cancer **2013**, 97-110		
77	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncology, The*, **2012**, 13, 385-94	21.7	612
76	Use of mutation profiles to refine the classification of endometrial carcinomas. *Journal of Pathology*, **2012**, 228, 20-30	9.4	227
75	The clonal and mutational evolution spectrum of primary triple-negative breast cancers. *Nature*, **2012**, 486, 395-9	50.4	1417
74	Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. *New England Journal of Medicine*, **2012**, 366, 234-42	59.2	332
73	14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 929-34	11.5	208

72	Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. *International Journal of Gynecological Cancer*, **2012**, 22, 9-14	3.5	77
71	It sounded like a good idea at the time. *Journal of Obstetrics and Gynaecology Canada*, **2012**, 34, 1127-1130	1.3	8
70	The role of the fallopian tube in ovarian cancer. *Clinical Advances in Hematology and Oncology*, **2012** , 10, 296-306	0.6	66
69	Molecular Pathology of Ovarian Carcinomas. *Surgical Pathology Clinics*, **2011**, 4, 275-96	3.9	1
68	FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. *American Journal of Surgical Pathology*, **2011**, 35, 484-94	6.7	143
67	Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. *Gynecologic Oncology*, **2011**, 121, 407-15	4.9	186
66	Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. *Journal of Pathology* , **2011**, 223, 567-73	9.4	98
65	Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. *Journal of Pathology*, **2011**, 224, 328-33	9.4	174
64	Using next-generation sequencing for the diagnosis of rare disorders: a family with retinitis pigmentosa and skeletal abnormalities. *Journal of Pathology*, **2011**, 225, 12-8	9.4	26
63	P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. *Modern Pathology*, **2011**, 24, 64-81	9.8	50
62	Calculator for ovarian carcinoma subtype prediction. *Modern Pathology*, **2011**, 24, 512-21	9.8	79
61	IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. *Clinical Cancer Research*, **2011**, 17, 2538-48	12.9	182
60	deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. *PLoS Computational Biology*, **2011**, 7, e1001138	5	409
59	De novo expression of CD44 variants in sporadic and hereditary gastric cancer. *Laboratory Investigation*, **2010**, 90, 1604-14	5.9	60
58	Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. *Journal of Medical Genetics*, **2010**, 47, 436-44	5.8	411
57	SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. *Bioinformatics*, **2010**, 26, 730-6	7.2	174
56	ARID1A mutations in endometriosis-associated ovarian carcinomas. *New England Journal of Medicine*, **2010**, 363, 1532-43	59.2	1208
55	Type I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer. *Breast Cancer Research*, **2010**, 12, R6	8.3	42

54	Periodic acid-schiff is superior to hematoxylin and eosin for screening prophylactic gastrectomies from CDH1 mutation carriers. *American Journal of Surgical Pathology*, **2010**, 34, 1007-13	6.7	11
53	Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. *American Journal of Surgical Pathology*, **2010**, 34, 984-93	6.7	119
52	HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. *Annals of Surgery*, **2010**, 251, 1107-16	7.8	42
51	Differences in tumor type in low-stage versus high-stage ovarian carcinomas. *International Journal of Gynecological Pathology*, **2010**, 29, 203-11	3.2	260
50	Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. *Breast Cancer Research and Treatment*, **2010**, 121, 347-54	4.4	31
49	Pregnancy after prophylactic total gastrectomy. *Familial Cancer*, **2010**, 9, 331-4	3	25
48	The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. *Journal of Pathology*, **2010**, 222, 191-8	9.4	115
47	Hereditary diffuse gastric cancer. *Cancer Treatment and Research*, **2010**, 155, 33-63	3.5	12
46	The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors. *PLoS ONE*, **2009**, 4, e7988	3.7	71
45	Germline CDH1 deletions in hereditary diffuse gastric cancer families. *Human Molecular Genetics*, **2009**, 18, 1545-55	5.6	159
44	Adult-type granulosa cell tumors and FOXL2 mutation. *Cancer Research*, **2009**, 69, 9160-2	10.1	49
43	Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. *BMC Cancer*, **2009**, 9, 165	4.8	53
42	HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. *BMC Cancer*, **2009**, 9, 433	4.8	141
41	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. *Modern Pathology*, **2009**, 22, 469-75	9.8	102
40	Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. *Nature*, **2009**, 461, 809-13	50.4	879
39	Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. *Gastroenterology*, **2009**, 136, 2137-48	13.3	128
38	Mutation of FOXL2 in granulosa-cell tumors of the ovary. *New England Journal of Medicine*, **2009**, 360, 2719-29	59.2	551
37	A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. *American Journal of Surgical Pathology*, **2009**, 33, 14-21	6.7	181

36	The fallopian tube: primary site of most pelvic high-grade serous carcinomas. *International Journal of Gynecological Cancer*, **2009**, 19, 58-64	3.5	147
35	Reply to Perner and Rubin. *Modern Pathology*, **2008**, 21, 1056-1057	9.8	
34	Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. *Breast Cancer Research*, **2008**, 10, R86	8.3	90
33	Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. *Breast Cancer Research*, **2008**, 10, R6	8.3	25
32	Hereditary diffuse gastric cancer: prophylactic surgical oncology implications. *Surgical Clinics of North America*, **2008**, 88, 759-78, vi-vii	4	32
31	Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. *PLoS Medicine*, **2008**, 5, e232	11.6	575
30	Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. *Breast Cancer Research and Treatment*, **2008**, 107, 249-57	4.4	140
29	Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. *Breast Cancer Research and Treatment*, **2008**, 110, 417-26	4.4	82
28	Hereditary diffuse gastric cancer: association with lobular breast cancer. *Familial Cancer*, **2008**, 7, 73-82	3	106
27	Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. *Cancer*, **2008**, 112, 2655-63	6.4	68
26	Amplification of 11q13 in ovarian carcinoma. *Genes Chromosomes and Cancer*, **2008**, 47, 481-9	5	101
25	Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. *Modern Pathology*, **2007**, 20, 1156-65	9.8	56
24	Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. *BMC Medicine*, **2007**, 5, 33	11.4	44
23	Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. *JAMA - Journal of the American Medical Association*, **2007**, 297, 2360-72	27.4	324
22	CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. *Annals of Surgery*, **2007**, 245, 873-9	7.8	133
21	Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. *Gynecologic Oncology*, **2006**, 100, 264-70	4.9	72
20	Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. *Journal of Clinical Oncology*, **2006**, 24, 5637-44	2.2	159
19	MDM2 protein expression is a negative prognostic marker in breast carcinoma. *Modern Pathology*, **2006**, 19, 69-74	9.8	55

18	Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. *Experimental Cell Research*, **2005**, 310, 99-104	4.2	46
17	Gastric cancer: new genetic developments. *Journal of Surgical Oncology*, **2005**, 90, 114-33; discussion 133	2.8	142
16	Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. *Clinical Cancer Research*, **2005**, 11, 5401-9	12.9	168
15	Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. *Journal of the National Cancer Institute*, **2005**, 97, 1302-6	9.7	32
14	The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. *Modern Pathology*, **2004**, 17, 690-5	9.8	104
13	Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. *Journal of Pathology*, **2004**, 203, 681-7	9.4	205
12	Mechanisms of monozygotic (MZ) twinning: a possible role for the cell adhesion molecule, E-cadherin. *American Journal of Medical Genetics Part A*, **2003**, 120A, 59-62		8
11	E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. *Human Molecular Genetics*, **2003**, 12, 3007-16	5.6	68
10	EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. *Cell*, **2003**, 115, 523-35	56.2	345
9	Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. *Human Pathology*, **2003**, 34, 1001-8	3.7	85
8	Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. *Human Molecular Genetics*, **2003**, 12, 575-82	5.6	145
7	Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. *Human Mutation*, **2002**, 19, 510-7	4.7	142
6	Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. *New England Journal of Medicine*, **2001**, 344, 1904-9	59.2	361
5	A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. *Nature Genetics*, **2000**, 26, 362-4	36.3	134
4	A new method for characterization and epitope determination of a lupus anticoagulant-associated neutralizing antiprothrombin antibody. *American Journal of Clinical Pathology*, **1997**, 107, 197-205	1.9	16
3	Non-coding Somatic Mutations Converge on the PAX8 Pathway in Epithelial Ovarian Cancer		1
2	Novel functional insights revealed by distinct protein-protein interactions of the residual SWI/SNF complex in SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type		3
1	Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma		1